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1. Introduction
Worldwide the prevalence of diabetes was estimated to be 2.8% in 2000 and 4.4% in 2030. The
total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million
in 2030 [1]. The spread will be higher in developing countries (69%) compared to developed
countries (20%). Most of diabetic patients will have type 2 diabetes [2].
Chronic kidney disease (CKD) is prevalent in people with diabetes; a recent analysis of
NHANES data found that 39.6% of people with diagnosed diabetes, 41.7% of those with
undiagnosed diabetes and 17.7% of those with prediabetes had CKD [3]. Increased urinary
protein excretion may be an early clinical manifestation of diabetic nephropathy. However,
when assessing protein excretion, the urine dipstick is a relatively insensitive marker for initial
increases in protein excretion, not becoming positive until protein excretion exceeds 300 to 500
mg/day (upper limit of normal less than 150 mg/day, with most individuals excreting less than
100 mg/day) [4]. Microalbuminuria is delimited as an albumin excretion rate of 30-300 mg/24
h or a spot urine albumin to creatinine Ratio (ACR) of 30-300 mg/g (3.5-35 mg/mmol) in males
and 20-200 mg/g (2.5-25 mg/mmol) in females. Overt diabetic nephropathy (DN) is settled by
proteinuria >500 mg/24 h or albuminuria >300 mg/24 h. Also DN can be defined by an estimated
glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 [5]. 5097 subjects with type 2
diabetes were followed from 1977 to 1997 to determine the rate of progression of kidney
disease. From diagnosis of diabetes, progression to microalbuminuria occurred at 2.0% per
year, from microalbuminuria to macroalbuminuria at 2.8% per year, and from macroalbumi‐
nuria to elevated plasma creatinine (>or=175 micromol/L) or renal replacement therapy (RRT)
at 2.3% per year. Ten years following diagnosis of diabetes, the prevalence of microalbumi‐
nuria was 24.9%, of macroalbuminuria was 5.3%, and of elevated plasma creatinine or RRT
was 0.8% [6]. Renal dysfunction, including proteinuria and microalbuminuria, is predictive of
cardiovascular events, and cardiovascular and all-cause mortality [7-11]. Although these cut-
offs defining normoalbuminuria, microalbuminuria, and macroalbuminuria facilitate deter‐
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mining the risk for progression of nephropathy, the risk of developing overt diabetic
nephropathy is probably directly related to albumin excretion rates at all levels. A recent
collaborative meta-analysis of general population cohorts involving more than 1 million
participants has provided strong evidence of the direct relationship between renal dysfunction
and cardiovascular risk [12]. eGFR < 60 ml/min/1.73 m 2 and (ACR) 1.1 mg/mmol (10 mg/g)
were both independent predictors of mortality risk in the general population. The two
parameters increased mortality in a multiplicative fashion, without evidence of interaction
[12]. The clinical significance, screening, prevention and management of proteinuria in patients
with type 2 diabetes will be reviewed here.
Mortality rates for those with nephropathy are high, increasing from 1.4% per year in nor‐
moalbuminuria to 4.6% per year (clinical grade proteinuria), and to 19.2% per year those with
renal impairment. More intensive blood glucose control resulted in both a 33% reduction in
relative risk of development of microalbuminuria or clinical grade proteinuria at 12 years, and
a significant reduction in the proportion doubling their plasma creatinine (0.91 vs. 3.52%, P =
0.0028). These data underline the importance of glycaemic and blood pressure control in type
2 diabetes in order to prevent diabetic nephropathy [13]. Asian and hispanic patients with type
2 diabetes had a high prevalence of proteinuria and reduced kidney function [14,15]. In
Caucasian non-insulin dependent diabetic baseline microalbuminuria, male gender, presence
of retinopathy, S-cholesterol, HbA1c, and age was found to predict the development of
incipient/overt diabetic nephropathy [16]. To estimate the frequency of remission/regression
of microalbuminuria and to identify factors affecting such outcomes 216 Japanese patients with
type 2 diabetes and microalbuminuria were enrolled and observed during an initial 2-year
evaluation period. Remission was defined as shift to normoalbuminuria and regression as a
50% reduction in urinary albumin excretion rate (UAER)from one 2-year period to the next.
Reduction of urinary UAER was frequent, with a 6-year cumulative incidence of 51% (95% CI
42-60) for remission and 54% for regression, whereas the frequency of progression to overt
proteinuria was 28%. Microalbuminuria of short duration, the use of renin-angiotensin system-
blocking drugs, and lower tertiles for HbA(1c) (<6.95%) and systolic blood pressure (<129
mmHg) were independently associated with remission or regression in the pooled logistic
regression analysis. Early detection of microalbuminuria and a multifactorial control may
result in improved outcomes for diabetic nephropathy and cardiovascular events [17].
2. Pathogenesis
Microalbuminuria and macroalbuminuria are not only markers of nephropathy but also causes
of disease progression. Proteinuria may accelerate kidney disease progression to end-stage
renal failure through multiple pathways, including induction of tubular chemokine expression
and complement activation that lead to inflammatory cell infiltration in the interstitium and
sustained fibrogenesis [18]. The precise mechanisms by which albumin leaves the bloodstream,
crosses the endothelial suface layer, glomerural endothelial fenestrae, the glomerural base‐
ment membrane, the sleet pores between the foot processes of the podocytes and the subpo‐
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docyte space and by which albumin passes through Bowman's space and the tubuli and at the
end enters into the urine remain an area of research and debate [19].
Glomerular hemodynamics and renin-angiotensin system (RAS). Proteinuria may be detected
in healthy people after sustained exercise. Unbalance between afferent artery and efferent
artery may appear during vigorous physical effort. Renal blood flow decreases and GFR is
maintained by increment in intraglomerural pressure. Intraglomerural hypertension induces
albuminuria. Also in DN, albuminuria is induced by a reduction in renal mass. Preserved
glomeruli compensate the sclerotic ones by dilatation of afferent arterioles, constriction of
efferent arterioles, increment of intraglomerural hydrostatic pressure. When this process
continues, the glomerular barrier is compromised and albumin enters into the urine [20]. Leak
of albumin into the urine is partly blocked by RAS inhibition also in healthy subjects [21]. RAS
plays a central role as a mediator of glomerural hemodynamic and injury. Therapeutic
blockade of RAS slows the disease progression not only by hemodynamic action but also by
induction of profibrotic agents. Angiotensin II (Ang II) also plays an important role in
glomerulosclerosis through induction of transforming growth factor –β (TGF- β) expression
in mesangial cell [22]. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) can attenuate progressive glomerulosclerosis without altering
glomerular pressures. Because agents that interfere with Ang II action may decrease glomer‐
ular injury, it has been suggested that Ang II has direct effects on glomerular cells to induce
sclerosis independent of its hemodynamic actions.Antagonizing the profibrotic effects of
angiotensin II may also be a significant factor in benefits observed with ACE inhibitors and
ARBS [22].
3. Endothelial barrier and glomerural basement membrane
The endothelium of glomerural capillaries is fenestrated. The diameter of endothelial pores is
60-100 nm. Although the albumin diameter is smaller than the pore diameter (8nm) the
endothelium is not working like a sieve [24]. A glycoprotein coat covers capillary endothelium
like a gel-like diaphragm. Damage of diaphragm in diabetic patients is associated with
proteinuria [25].
The glomerural basement membrane was considered a mechanical and electrostatic barrier.
The loss negatively charged proteoglycans is associated with albumin cross. Today,the
mechanical role of glomerural basement membrane is less important [14,26]. Although the
glomerural basement membrane is thick in diabetic patients, the leakage of albumin is
increased [26].
4. Podocytes
Podocytes are highly specialized cells of the kidney glomerulus that help to prevent protei‐
nuria through regulation of the actin cytoskeleton in their foot processes. Podocytopenia
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correlates with disease progression and is related inversely to the control of hypertension and
diabetes. Diabetes mellitus induces podocytopenia through several mechanisms.
Podocyte morphological changes in DN are flattening and retraction. Podocyte dysfunction
reduces ultrafiltration and induces intraglomerural hypertension and proteinuria. Podocytes
are detected in the urine of diabetic patients and proves that this type of cells are in a prolif‐
eration apoptosis cycle [27].
Defects in podocyte-specific insulin signaling may contribute to diabetic nephropathy. Two
mouse models have been engineered in which the gene encoding the insulin receptor from the
podocyte is deleted [28]. In the absence of hyperglycemia, affected mice develop albuminu‐
ria,  effacement  of  foot  processes,  apoptosis,  glomerular  basement  membrane thickening,
accumulation of mesangial matrix and glomerulosclerosis. Activation of the insulin receptor
appears to trigger remodeling of the actin cytoskeleton through the mitogen-activated protein
kinase 42/44 (MAPK) and phosphatidylinositol 3 (PI3) kinase signaling pathways, suggesting
a possible mechanism of proteinuria. The podocyte insulin receptor is an attractive target for
agents that prevent proteinuria and development and progression of diabetic nephropathy [29].
Podocytes are linked by a porous diaphragm with pores diameter of 12 nm. The integrity of
the diaphragm has a great importance in prevention of proteinuria, Several diaphragm protein
mutations like nephrin and podocin are associated with nephritic syndrome. When compared
with nondiabetic patients with minimal change nephropathy and controls, patients with
diabetic nephropathy had a downregulation of nephrin expression and fewer electron dense
slit diaphragms [30].
5. Bowman ‘s space and proximal tubule
Bowman’s space is situated between the parietal layer of Bowman’s capsule and podocytes.
Bowman’s space is important in ultrafiltration and hydraulic resistance. The hydrostatic
pressure is reduced in diabetic patients and appears to be associates with albuminuria [31].
Tubules suffer a number of structural and functional changes in DN. Tubules are hypertrophic
and tubular basement membrane is thickened before proteinuria appearance. Tubular
filtration is impaired through several mechanisms: lysosomal dysfunction; albumin trans‐
porters’ reduction like megalin and cubilin; apical brush border changes and cathepsin-
mediated proteolytic activity decrease [32,33].
Advanced Glycation End Products (AGEs) AGEs are the product of nonenzymatic reaction
between the aldehyde group of sugars and carbonyls of proteins, lipids and nucleic acids. The
first stable product is Amadori complex like HBA1c [34]. AGEs induce mesangial expansion
and injury, through activation of AGE receptors (RAGE) perhaps in part via increased matrix
production or glycation of matrix proteins [34]. The potential significance of RAGE in diabetic
kidney is demonstrated by prevention of indices of mesangial expansion, thickening of the
glomerural basement membrane and reduced albuminuria in RAGE knockout (KO) mice and
following intervention with RAGE antibodies; on the other hand RAGE activation may
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produce renal damage [35,36]. The net effect is tissue accumulation of AGEs, in part by
crosslinking with collagen, which can contribute to the associated renal and microvascular
complications [37].
Prorenin — Renin is an aspartyl-protease that exists in two forms, the proenzyme prorenin
and mature renin. Prorenin is transformed into mature renin by cleavage of the 43 amino acids
of the pro-segment. Prorenin, although synthesized by a restricted number of tissues, repre‐
sents up to 90% of total plasma renin in normal subjects. Experimental data on transgenic rats
confirm a link between the overexpression of the receptor and cardiovascular and renal
dysfunctions possibly involving direct activation of the receptor by (pro)renin [38]. Prorenin
receptor blockade with a short peptide of prorenin practically abolished the increased mitogen-
activated protein kinase (MAPK) activation and nephropathy despite unaltered increase in
AngII in diabetic kidney. These results indicate that the MAPK activation signal leads to the
diabetic nephropathy but not other renin-angiotensin system-activated mechanisms in the
glomeruli. It is not only AngII but also intraglomerular activation of MAPK by the receptor-
associated prorenin that plays a pivotal role in diabetic nephropathy [39].
Cytokines — Angiogenetic factors may explain pathologic changes in DN. Vascular endothe‐
lial growth factor (VEGF) is one of the main angiogenetic factors. Its expression and signaling
in the kidney are amplified early on in the diabetic state. Moreover, counteracting its effects
reverses the albuminuria and other hemodynamic and structural features of experimental DN.
Finally, experimental overexpression of VEGF in adult mice replicates several aspects of
diabetic kidney disease [41]. Under the influence of a variety of diabetic mediators, the
podocyte becomes the main source of increased expression of VEGF in the kidney. The cytokine
then exerts its multitude of effects in an autocrine fashion on the podocyte itself, on the
endothelial cell in a paracrine manner, and finally contributes to macrophage recruitment
acting as a chemokine [41,42]. The angiopoietins consist primarily of two main factors acting
in contrast to each other: Ang I--an antiangiogenic ligand, and Ang II--its competitive inhibitor.
Both, however, seem to have important roles in the maintenance of glomerular homeostasis
[43]. Diabetes disrupts the tight balance that controls angiopoietin expression and function
and decreases theAngI/AngII ratio. The end physiologic result seems to be dependent on the
concomitant VEGF changes in the kidney. Because of the intricacy of their control, angiogenic
factors are difficult to manipulate therapeutically [41,43].
TGF- β is a key factor in the development of diabetic complications by activating downstream
mediators called Smad2 and Smad3. Hyperglycemia can induce TGF- β and Smads stimulation
and renal fibrosis through MAPK and NF-kB pathways [44]
6. Detection and screening
Establishing the diagnosis of microalbuminuria requires the demonstration of an elevation in
albumin excretion (30 to 300 mg/day). An elevated ratio should be confirmed with at least two
additional tests performed over the subsequent three to six months, with confirmation of the
diagnosis requiring at least two of three positive samples [45]. Patients with diabetes mellitus
Diabetes Mellitus Type 2 and Proteinuria
http://dx.doi.org/10.5772/56434
209
type 2 must be screened annually, starting at diagnosis. Fever, exercise, heart failure, and poor
glycemic control are among the factors that can cause transient microalbuminuria [46]. There
are many methods to screen for abnormal amounts of proteinuria to identify patients at risk
for progression of renal disease. 701 patients with type 2 diabetes and nephropathy partici‐
pating in the Reduction of Endpoints in Non Insulin Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan (RENAAL) trial were enrolled to compare the ability of
urinary protein excretion (UPE) and urinary albumin excretion (UAE) from a 24-hour urine
collection and urinary albumin concentration (UAC) and the albumin:creatinine ratio (ACR)
from a first-morning void in predicting renal events. The primary outcome measure was the
time to a doubling of serum creatinine or end-stage renal disease. During follow-up, 202 events
occurred. The hazard ratios for the risk of a renal outcome (95% CIs) associated with 1-SD
increment in the log-transformed measures were 3.16 (2.60 to 3.86) for UAE, 3.02 (2.53 to 3.62)
for UPE, 3.23 (2.67 to 3.91) for UAC, and 4.36 (3.50 to 5.45) for ACR. The area under the ROC
curve was significantly higher for ACR compared with the other measures. In conclusion,
measurement of the albumin:creatinine ratio in a first-morning void is the superior method to
predict renal events in patients with type 2 diabetes and nephropathy,but the difference
compared to spot urine samples at other times was not significant [46,47]. The recommended
albumin (microg)/creatinine (mg) ratio (ACR) (30 microg/mg) to detect microalbuminuria does
not account for sex or racial differences in creatinine excretion. Mean urine albumin concen‐
tration were not significantly different between men and women, but urine creatinine
concentrations is significantly higher. No significant difference in the prevalence of microal‐
buminuria between men and women was noted when sex-specific ACR cutpoints are used (>
or =17 microg/mg in men and > or =25 microg/mg in women). The use of one ACR value to
define microalbuminuria may underestimate microalbuminuria in subjects with higher
muscle mass (men) and possibly members of certain racial/ethnic groups [48]. The most
pronounced benefits of glycaemic control are on retinal and renal complications in both
normoalbuminuric and microalbuminuric patients considered together, with little or no
evidence of any greater benefit in those with microalbuminuria. Hence, microalbuminuric
status may be a false boundary when considering the benefits of glycaemic control. Classifi‐
cation of a person as normoalbuminuric must not serve to suggest that they will derive less
benefit from optimal glycaemic control than a person who is microalbuminuric. All hyperten‐
sive patients benefit from blood pressure lowering [49].
7. Treatment and prevention
Glycemic and blood pressure control, particularly with angiotensin converting enzyme (ACE)
inhibitors or angiotensin II receptor blockers (ARBs), have shown to reduce proteinuria,
preserve renal function in diabetic patients and reduce cardiovascular events [50].
Lifestyle improvement is the first step in the treatment of DN. This includes a number of
measures: avoidance or cessation of smoking, weight reduction and maintaining body mass
index (BMI) between 18.5 and 24.9; physical activity, especially regular aerobic physical
activity such as brisk walking for more than 30 minutes per day, most days of the week; low
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protein diet and reducing protein intake to 0.8-1.0 g/kg body weight per day, most days of the
week; low sodium intake to less than 100 mmol /d (2.4 g of sodium or 6 g of sodium chloride)
consuming a diet rich in fruits, vegetables, and low fat diary products (DASH diet); low alcohol
intake, not more than two drinks for men and one drink for women). For patients with diabetes,
clinical practice guidelines recommend treating to a low-density lipoprotein cholesterol (LDL-
C) goal of < 100 mg/dL and <70 mg/dl for very high risk patients, using statins as first line
treatment [46,51].
8. Blood pressure control and renin-angiotensin blockade
All current guidelines recommend a blood pressure goal in patients with diabetes <130 ⁄ 80
mm Hg. The proportion of diabetic individuals taking lipid- and BP-lowering agents has
increased significantly in recent years. However, while there has been a significant improve‐
ment in LDL-C goal attainment, nearly one-half of all U.S. adults with diabetes are not at
recommended LDL-C or BP treatment goals [52]. Patients with HTN and diabetes have a 7-
fold greater risk for progressing to end-stage renal disease (ESRD) and 2 to 4-fold greater risk
of developing cardiovascular disease. The first lone treatment are ACEI and ARBS due to
renoprotective effect [53,54]. If the baseline BP is >150 ⁄ 90 mm Hg, a second agent should be
added, preferably a thiazide diuretic, because they can add cardiovascular protection [54,55].
However, recent evidence suggests that calcium channel blockers, especially amlodipine can
comparatively reduce cardiovascular events [56].
Several clinical trials have proved evidence that the conventional treatments for renoprotection
including blood pressure regulation, tight glucose control, renin-angiotensin system inhibi‐
tion, lifestyle modifications and medical team improvement reduce the morbidity and
mortality associated with proteinuria. The benefit of ACEI and ARBS in reducing proteinuria
and renal preservation in DN has been confirmed in several large randomized trials. Some of
them are summarized in Table 1 and detailed in this paragraph.
9. ACEI
In a randomized, double-blind, placebo-controlled trial 94 patients with normal blood pressure
and microalbuminuria were assigned to receive enalapril, 10 mg per day, or placebo. After 5
years albuminuria decreased from 143 +/- 64 (mg/24 h to 122 +/- 67 mg/24 h during the first year.
In the placebo group microalbuminuria slowly increased to 140 +/- 134 mg/24 [P<0.05]). Kidney
function (expressed as mean reciprocal creatinine) declined by 13% in the placebo group and
remained stable (-1%) in the enalapril group (P<0.05) [57]. Later this study was done on diabetic
patients with normal blood pressure and normoalbuminuria. In a randomized, double-blind,
placebo-controlled trial, 156 patients were assigned to receive enalapril, 10 mg/d, or placebo for
a period of 6 years. Enalapril therapy decreased albumin excretion from 11.6 +/- 7 mg/24 h to
9.7 +/- 6 mg/24 h at 2 years. This was followed by a gradual increase to 15.8 +/- 8 mg/24 h at 6
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years. In the placebo group, albumin excretion increased from 10.8 +/- 8 mg/24 h to 26.5 +/- 10
mg/24 h at 6 years (P = 0.001 for enalapril compared with placebo). Transition to microalbumi‐
nuria occurred in 15 of 79 (19%) placebo recipients and 5 of 77 (6.5%) enalapril recipients.
Enalapril treatment resulted in an absolute risk reduction of 12.5% (95% CI, 2% to 23%; P = 0.042)
for development of microalbuminuria. After 6 years, creatinine clearance decreased from 1.78
+/- 0.13 mL/s to 1.63 +/- 0.12 mL/s (mean decrease, 0.025 mL/s per year) in enalapril recipients
and from 1.81 +/- 0.15 mL/s to 1.57 +/- 0.17 mL/s (mean decrease, 0.04 mL/s per year) in placebo
recipients (P = 0.040) [58].
10. ARBS
In IRMA-2 (Irbesartan Microalbuminuria in Hypertensive Patients with Type 2 Diabetes),the
renoprotective effect of the angiotensin-II-receptor antagonist irbesartan independently of its
blood-pressure-lowering effect was evaluated in hypertensive patients with type 2 diabetes
and microalbuminuria. 590 patients were enrolled in a randomized, double-blind, placebo-
controlled study of irbesartan, at a dose of either 150 mg daily or 300 mg daily, and were
followed for two years. The primary outcome was the time to the onset of diabetic nephrop‐
athy, defined by persistent albuminuria in overnight specimens, with a urinary albumin
excretion rate that was greater than 200 ucg per minute and at least 30 percent higher than the
base-line level. Ten of the 194 patients in the 300-mg group (5.2 percent) and 19 of the 195
patients in the 150-mg group (9.7 percent) reached the primary end point, as compared with
30 of the 201 patients in the placebo group (14.9 percent) (hazard ratios, 0.30 [95 percent
confidence interval, 0.14 to 0.61; P<0.001]and 0.61 [95 percent confidence interval, 0.34 to 1.08;
P=0.081 for the two irbesartan groups, respectively) [59]. The Angiotensin II Antagonist
Losartan (RENAAL) study investigated renoprotective role of albuminuria reduction in 1428
patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction
of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study.
Among patients with a reduced blood pressure during treatment, a lack of albuminuria
reduction was observed in 37, 26, and 51% (total, losartan, and placebo, respectively) at month
6. Blood pressure or albuminuria reduction was associated with a lower risk for end stage renal
failure, whereas combined blood pressure and albuminuria reduction was associated with the
lowest risk for events [60]. The MicroAlbuminuria Reduction With VALsartan (MARVAL)
study investigated the BP-independent effect of valsartan to reduce microalbuminuria in type
2 diabetic patients. Three hundred thirty-two patients with type 2 diabetes and microalbumi‐
nuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d
amlodipine for 24 weeks. The primary end point was the percent change in UAER from
baseline to 24 weeks. The UAER at 24 weeks was 56% (95% CI, 49.6 to 63.0) of baseline with
valsartan and 92% (95% CI, 81.7 to 103.7) of baseline with amlodipine, a highly significant
between-group effect (P<0.001). Valsartan lowered UAER similarly in both the hypertensive
and normotensive subgroups. More patients reversed to normoalbuminuria with valsartan
(29.9% versus 14.5%; P=0.001)., valsartan lowered UAER more effectively than amlodipine in
patients with type 2 diabetes and microalbuminuria, including the subgroup with baseline
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normotension [61]. In ROADMAP trial olmesartan was associated with a delayed onset of
microalbuminuria, even though blood-pressure control in both groups was excellent according
to current standards [62]. Although in other studies ARBS were effective in reducing cardio‐
vascular morbidity and mortality as well as mortality from all causes in patients with hyper‐
tension, diabetes, and left ventricular hypertrophy, in ROADMAP study the higher rate of fatal
cardiovascular events with olmesartan among patients with preexisting coronary heart disease
is of concern [62,63]. Several trials do not permit a conclusion about the efficacy of angiotensin
inhibition for the prevention of new onset microalbuminuria in normotensive patients with
type 2 diabetes. The DIRECT (Diabetic Retinopathy Candesartan Trials) Program are three
randomized studies. 3326 and 1905 patients with type 1 and type 2 diabetes, respectively, most
were normotensive, and all had normoalbuminuria (median urinary albumin excretion rate,
5.0 microg/min) were assigned to receive candesartan, 16 mg/d increasing to 32 mg/d, versus
placebo, for a period of 4.7 years. The primary end point was new microalbuminuria (3 or 4
collections of urinary albumin excretion rate>or=20 microg/min). Individual and pooled results
of the 3 trials showed that candesartan had little effect on risk for microalbuminuria (pooled
hazard ratio, 0.95 [95% CI, 0.78 to 1.16]; P = 0.60). Pooled results showed that the annual rate
of change in albuminuria was 5.53% lower (CI, 0.73% to 10.14%; P = 0.024) with candesartan
than with placebo. Candesartan, 32 mg/d, for 4.7 years did not prevent microalbuminuria in
mainly normotensive patients with type 1 or type 2 diabetes [64]. The normotensive Appro‐
priate Blood pressure Control in Diabetes (ABCD) trial study investigated the effect of
intensive versus moderate diastolic blood pressure (DBP) control on diabetic vascular
complications in 480 normotensive type 2 diabetic patients. 480 patients randomized to
intensive (10 mm Hg below the baseline DBP) versus moderate (80 to 89 mm Hg) DBP control.
Patients in the moderate therapy group were given placebo, while the patients randomized to
intensive therapy received either nisoldipine or enalapril in a blinded manner for 5.3 years.
The primary end point evaluated was the change in creatinine clearance with the secondary
endpoints consisting of change in urinary albumin excretion, progression of retinopathy and
neuropathy and the incidence of cardiovascular disease. Mean BP in the intensive group was
128 +/- 0.8/75 +/- 0.3 mm Hg versus 137 +/- 0.7/81 +/- 0.3 mm Hg in the moderate group, P<0.0001.
Although no difference was demonstrated in creatinine clearance (P = 0.43), a lower percentage
of patients in the intensive group progressed from normoalbuminuria to microalbuminuria (P
= 0.012) and microalbuminuria to overt albuminuria (P = 0.028). The intensive BP control group
also demonstrated less progression of diabetic retinopathy (P = 0.019) and a lower incidence
of strokes (P = 0.03). The results were the same whether enalapril or nisoldipine was used as
the initial antihypertensive agent [65].
11. ACEI and ARBS
A number of trials were designed to address the lack of comparative data on the long-term
effects of ARBS versus ACEI on renoprotection. The Diabetics Exposed to Telmisartan And
enalaprIL (DETAIL) trial is a randomized comparative of these agents. 250 patients with type
2 diabetes and early nephropathy as defined by albuminuria (82 percent microalbuminuria
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and 18 percent macroalbuminuria to a maximum of 1.4 g/day) and a baseline GFR (measured
isotopically) of approximately 93 mL/min per 1.73 m2 patients were assigned to receive an
ACEI, enalapril to an ARB,telmisartan. A greater fall in GFR of at least 10.0 mL/min per 1.73
m2 at five years was predefined as suggesting a clinically significant difference between the
two treatment groups.At five years, there was a smaller decline in GFR with enalapril that was
not significant (14.9 versus 17.9 mL/min per 1.73 m2 with telnmisartan). Both groups had
similar rates or findings for the secondary end points, which included annual changes in the
GFR, blood pressure, serum creatinine concentration, urinary albumin excretion, end-stage
kidney disease, cardiovascular events, and mortality [66]. In the candesartan and lisinopril
microalbuminuria (CALM) study was assessed and compared the effects of candesartan or
lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microal‐
buminuria, hypertension, and type 2 diabetes. Candesartan 16 mg once daily, lisinopril 20 mg
once daily were administered to 199 patients in a prospective, randomised, parallel group,
double blind study.It run in period and 12 weeks' monotherapy with candesartan or lisinopril
followed by 12 weeks' monotherapy or combination treatment. the reduction in urinary
albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater
than with candesartan (24%, 0% to 43%, P=0.05) and lisinopril (39%, 20% to 54%, P<0.001) [67].
In other trials the benefit of combination therapy of ACEI along with ARB reduce proteinuria
to a greater extent than monotherapy, overall it worsens major renal outcomes [ 68 ]. The
ONTARGET study investigated the renal effects of ramipril (an ACE inhibitor), telmisartan
(an ARB), and their combination in patients aged 55 years or older with established athero‐
sclerotic vascular disease or with diabetes with end-organ damage. The trial ran for six years.
After a 3-week run-in period, 25 620 participants were randomly assigned to ramipril 10 mg
a day (n=8576), telmisartan 80 mg a day (n=8542), or to a combination of both drugs (n=8502;
median follow-up was 56 months), and renal function and proteinuria were measured. The
primary renal outcome was a composite of dialysis, doubling of serum creatinine, and death.
The number of events for the composite primary outcome was similar for telmisartan (n=1147
[13.4%]) and ramipril (1150 [13.5%]; hazard ratio [HR] 1.00, 95% CI 0.92-1.09), but was increased
with combination therapy (1233 [14.5%]; HR 1.09, 1.01-1.18, p=0.037). The secondary renal
outcome, dialysis or doubling of serum creatinine, was similar with telmisartan (189 [2.21%])
and ramipril (174 [2.03%]; HR 1.09, 0.89-1.34) and more frequent with combination therapy
(212 [2.49%]: HR 1.24, 1.01-1.51, p=0.038). Estimated glomerular filtration rate (eGFR) declined
least with ramipril compared with telmisartan (-2.82 [SD 17.2] mL/min/1.73 m(2)vs -4.12 [17.4],
p<0.0001) or combination therapy (-6.11 [17.9], p<0.0001). The increase in urinary albumin
excretion was less with telmisartan (p=0.004) or with combination therapy (p=0.001) than with
ramipril [68]. The ORIENT study examined the effects of olmesartan, an ARB, on primary
composite outcome of doubling of serum creatinine, endstage renal disease and death in type
2 diabetic patients with overt nephropathy [69]. Secondary outcome included composite
cardiovascular outcomes, changes in renal function and proteinuria. Five hundred and
seventy-seven (377 Japanese, 200 Chinese) patients treated with antihypertensive therapy
(73.5% ) received concomitant ACEI), were given either once-daily olmesartan (10-40 mg) or
placebo over 3.2 years (In the olmesartan group, 116 developed the primary outcome (41.1%)
compared with 129 (45.4%) in the placebo group (HR 0.97, 95% CI 0.75, 1.24; p=0.791). Olme‐
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sartan significantly decreased blood pressure, proteinuria and rate of change of reciprocal
serum creatinine. Cardiovascular death was higher in the olmesartan group than the placebo
group (ten vs three cases), whereas major adverse cardiovascular events (cardiovascular death
plus non-fatal stroke and myocardial infarction) and all-cause death were similar between the
two groups (major adverse cardiovascular events 18 vs 21 cases, all-cause deaths; 19 vs 20
cases). Hyperkalaemia was more frequent in the olmesartan group than the placebo group
(9.2% vs 5.3%) [69]. The benefit of the combined use of a renin-angiotensin system inhibitor
with other antihypertensive drugs such as diuretics or nondihydropyridine calcium channel
blockers was studied.
12. Aliskiren, spironolactone and others
The ADVANCE trial investigated if controlling the blood pressure with a fixed combination
of perindopril and indapamide or matching placebo, in addition to current therapy reduces
the risks of major macrovascular and microvascular events, defined as death from cardiovas‐
cular disease, non-fatal stroke or non-fatal myocardial infarction, and new or worsening renal
or diabetic eye disease.
Study Patient population and duration Treatment Primary endpoint Benefit andoutcomes
Ravid (1993)
[57]
Normotensive+microalbuminuria
( 5 years) Enalapril vs placebo
Microalbuminuria
reduction Confirmed
Ravid (1998)
[58]
Normotensive+normoalbuminuria
( 6 years) Enalapril vs placebo
Albuminuria
prevention Confirmed
IRMA-2
[59]
Hypertension+microalbuminuria
( 2 years) Irbesartan vs placebo
Albuminuria
reduction
Confirmed,
independently of BP
RENAAL
[60]
Hypertension+microalbuminuria
(6 months) Losartan vs placebo
Albuminuria
reduction
Confirmed,
independently of BP
MARVAL
[61]
Hypertension(or normotensive)
+microalbuminuria
(24 weeks)
Valsartan vs placebo Albuminuriareduction
Confirmed,
independently of BP
ROADMAP
[62]
Hypertension +normoalbuminuria
(3.2 years) Olmesartan vs. placebo
Albuminuria
prevention
Confirmed
Higher fatal CV
events
ABCD
[65]
Hyper or normotension without
overt DN (5 years)
Intensive / standard BP
treatment
Overt DN
prevention and
reduction
Overt DN can not be
reversed
DIRECT
[64]
Normotensive+normoalbuminuria
( 4.7 years) Candesartan vs placebo
Albuminuria
prevention
Did not prevent
microalbuminuria
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Study Patient population and duration Treatment Primary endpoint Benefit andoutcomes
DETAIL
[66]
Hypertension+microalbuminuria
(5 years) Telmisartan vs enalapril
Noniferiority
renoprotection Confirmed
CALM
[67]
Hypertension+microalbuminuria
(24 weeks)
Candesartan+lisnopril vs
candesartan vs lisinopril
BP control and
microalbunuria
reduction
Superiority of
combination
confirmed
ONTARGET
[68]
Hypertension +end organ damage
(6 years)
Telmisartan+ramipril vs
telmisartan vs ramipril
Proteinuria and
renal failure
improvement
Combination
worsened renal
failure
ORIENT
[69]
Overt DN
(3.2 years) Olmesaran +ACEI vs ACEI
Proteinuria and
renal failure
improvement
Cobination did not
improved
ADVANCE
[70]
Hypertension
(4.3 years)
Perindopril+ indapamide
vs placebo
Macrro and
microvascular
events reduction
Confirm combined
but not separetly
BENEDICT
[71]
Hypertension +normoalbuminuria
(3.0 years)
Trandolapril+verapamil
vs trandolapril
Albuminuria
prevention
Verapamil similar to
placebo
AVOID
[72]
Hypertension+microalbuminuria
(6 months)
Aliskiren+losartan
vs.losartan
Albuminuria
reduction
Confirmed,
independently of BP
Mehdi (2009)
[73]
Hypertension+Overt DN
(48 weeks)
Spironolactone+lisino. vs
losartan+lisino. vs
lisinopril
Albuminuria
reduction
Combination with
spironolactone is
superior
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; BP, blood pressure; CV,cardio vascular; DN, diabetic
nephropathy;.Lisino, lisinopril. Clinical studies: ABCD, The normotensive Appropriate Blood pressure Control in Diabetes;
AVOID, Aliskiren in the Evaluation of Proteinuria in diabetes ; ADVANCE, Action in Diabetes and Vascular disease: PreterAx
and DiamicroN MR Controlled Evaluation; BENEDICT, Bergamo Nephrologic Diabetes Complications Trial CALM,
candesartan and lisinopril microalbuminuria; DETAIL, Diabetics Exposed to Telmisartan And enalaprIL; DIRECT, Diabetic
Retinopathy Candesartan Trials; IRMA-2, Irbesartan Microalbuminuria in Hypertensive Patients with Type 2 Diabetes;
MARVAL,MicroAlbuminuria Reduction With VALsartan ; ONTARGET, Ongoing telmisartan alone and in combination with
ramipril global endpoint trial; ORIENT, Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephrop‐
athy Trial; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention
Table 1. The benefit of ACEI and ARBS in reducing proteinuria and renal preservation in DN, summary of studies.
11 140 patients with type 2 diabetes were randomised to treatment. After a mean of 4.3 years
of follow-up, patients assigned to therapy had a mean reduction in systolic blood pressure of
5.6 mm Hg and diastolic blood pressure of 2.2 mm Hg. The relative risk of a major macrovas‐
cular or microvascular event was reduced by 9% (861 [15.5%]active vs 938 [16.8%]placebo;
hazard ratio 0.91, 95% CI 0.83-1.00, p=0.04). The separate reductions in macrovascular and
microvascular events were similar but were not independently significant (macrovascular 0.92;
0.81-1.04, p=0.16; microvascular 0.91; 0.80-1.04, p=0.16). The relative risk of death from
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cardiovascular disease was reduced by 18% (211 [3.8%] active vs 257 [4.6%] placebo; 0.82,
0.68-0.98, p=0.03) and death from any cause was reduced by 14% (408 [7.3%] active vs 471
[8.5%] placebo; 0.86, 0.75-0.98, p=0.03) [70]. Bergamo Nephrologic Diabetes Complications
Trial (BENEDICT) evaluated the effect of calcium channel blockers to prevent albuminuria
alone or along with ACEI. studied 1204 subjects, who were randomly assigned to receive at
least three years of treatment with trandolapril (at a dose of 2 mg per day) plus verapamil
(sustained-release formulation, 180 mg per day), trandolapril alone (2 mg per day), verapamil
alone (sustained-release formulation, 240 mg per day), The primary end point was the
development of persistent microalbuminuria (overnight albumin excretion,>or =20 ucg per
minute at two consecutive visits). The primary outcome was reached in 5.7 percent of the
subjects receiving trandolapril plus verapamil, 6.0 percent of the subjects receiving trando‐
lapril, 11.9 percent of the subjects receiving verapamil, and 10.0 percent of control subjects
receiving placebo. The estimated acceleration factor (which quantifies the effect of one
treatment relative to another in accelerating or slowing disease progression) adjusted for
predefined baseline characteristics was 0.39 for the comparison between verapamil plus
trandolapril and placebo (P=0.01), 0.47 for the comparison between trandolapril and placebo
(P=0.01), and 0.83 for the comparison between verapamil and placebo (P=0.54). Trandolapril
plus verapamil and trandolapril alone delayed the onset of microalbuminuria by factors of 2.6
and 2.1, respectively. Serious adverse events were similar in all treatment groups. The effect
of verapamil alone was similar to that of placebo [71]. Aliskiren is an direct renin inhibitor
blocks the conversion from angiotensinogen to angiotensin I. In the AVOID (Aliskiren in the
Evaluation of Proteinuria in Diabetes) study 599 patients with hypertension and type 2 diabetes
with nephropathy were randomized to receive aliskiren (150 mg daily for 3 months, followed
by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to
losartan. The primary outcome was a reduction in the ratio of albumin to creatinine. The mean
urinary albumin-to-creatinine ratio was reduced by 20% (95% confidence interval, 9 to 30;
P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as
compared with 12.5% of those who received placebo (P<0.001). Aliskiren may have renopro‐
tective effects that are independent of its blood-pressure-lowering effect in patients with
hypertension, type 2 diabetes, and nephropathy who are receiving the recommended reno‐
protective treatment [72]. Aldosterone receptor antagonist, such as spironolactone, has been
shown to to reduce proteinuria, when added to ACEI or ARBS. A double-blind, placebo-
controlled trial investigated 81 patients with diabetes, hypertension, and albuminuria (urine
albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily). The
patients were assigned to placebo, losartan (100 mg daily), or spironolactone (25 mg daily) for
48 wk. Compared with placebo, the urine albumin-to-creatinine ratio decreased by 34.0% (95%
CI, -51.0%, -11.2%, P = 0.007) in the group assigned to spironolactone and by 16.8% (95% CI,
-37.3%, +10.5%, P = 0.20) in the group assigned to losartan [73]. An interesting study assessed
the effect of die tary sodium restriction on the efficacy of losartan in hypertensive subjects with
type 2 diabetes and albumin excretion rates of 10-200 ucg/min. 20 subjects were randomized
to losartan 50 mg/day (n = 10) or placebo (n = 10). Drug therapy was given in two 4-week phases
separated by a washout period. In the last 2 weeks of each phase, patients were assigned to
low- or regular-sodium diets, in random order. In each phase, 24-h ambulatory blood pressure,
Diabetes Mellitus Type 2 and Proteinuria
http://dx.doi.org/10.5772/56434
217
urinary albumin-to-creatinine ratio (ACR), and renal hemodynamics were measured. Ach‐
ieved urinary sodium on a low-sodium diet was 85 +/- 14 and 80 +/- 22 mmol/day in the losartan
and placebo groups, respectively. In the losartan group, the additional blood pressure-
lowering effects of a low-sodium diet compared with a regular-sodium diet for 24-h systolic,
diastolic, and mean arterial blood pressures were 9.7 mmHg (95% confidence interval [CI],
2.2-17.2; P = 0.002), 5.5 mmHg (2.6-8.4; P = 0.002), and 7.3 mmHg (3.3- 11.3; P = 0.003), respec‐
tively. In the losartan group, the ACR decreased significantly on a low-sodium diet versus on
a regular-sodium diet (-29% [CI -50.0 to -8.5%] vs. + 14% [-19.4 to 47.9%], respectively; P = 0.02).
There was a strong correlation between fall in blood pressure and percent reduction in the
ACR (r = 0.7, P = 0.02). In the placebo group, there were no significant changes in blood pressure
or ACR between regular- and low-sodium diets [74].
13. Glycemic control
Poor glycemic control is a risk factor for both the development of microalbuminuria and for
progression to macroalbuminuria in patients with type 2 diabetes. Strict glycemic control is
recommended in all patients because of its beneficial effects on the microvascular complica‐
tions. Whilst the benefits of intensive glycemic therapy for people with diabetes and microal‐
buminuria have been well established, controversy remains as to whether intensive therapy
slows the progression of established DN, particularly among individuals who have a reduced
glomerular filtration rate. In addition, severe hypoglycemia has been associated with intensive
glycemic therapy, raising safety concerns that may be of particular relevance for patients with
decreased kidney function [75].
14. The ADVANCE study
The  ADVANCE  study  investigated  a  strategy  of  intensive  glucose  control,  involving
gliclazide  (modified  release)  and  other  drugs  as  required,  that  lowered  the  glycated
hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of
major macrovascular and microvascular events, primarily as a consequence of a 21% relative
reduction in nephropathy. 11,140 patients with type 2 diabetes were assigned to undergo
either standard glucose control or intensive glucose control,  defined as the use of glicla‐
zide (modified release) plus other drugs as required to achieve a glycated hemoglobin value
of 6.5% or less. Primary end points were composites of major macrovascular events (death
from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major
microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly
and separately. Intensive control reduced the incidence of combined major macrovascular
and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95%
confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events
(9.4% vs.  10.9%; hazard ratio,  0.86;  95% CI,  0.77 to 0.97;  P=0.01),  primarily because of  a
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reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66
to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50) [76].
15. UKPDS
In UKPDS the effects of intensive blood-glucose control with either sulphonylurea or insulin
and conventional treatment on the risk of microvascular and macrovascular complications in
patients with type 2 diabetes in a randomised controlled trial. 3867 newly diagnosed patients
with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment
had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were
randomly assigned intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or
glipizide) or with insulin, or conventional policy with diet. The aim in the intensive group was
FPG less than 6 mmol/L. In the conventional group, the aim was the best achievable FPG with
diet alone; drugs were added only if there were hyperglycaemic symptoms or FPG greater
than 15 mmol/L. Three aggregate endpoints were used to assess differences between conven‐
tional and intensive treatment: any diabetes-related endpoint (sudden death, death from
hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, heart
failure, stroke, renal failure, amputation [of at least one digit], vitreous haemorrhage, retin‐
opathy requiring photocoagulation, blindness in one eye, or cataract extraction); diabetes-
related death (death from myocardial infarction, stroke, peripheral vascular disease, renal
disease, hyperglycaemia or hypoglycaemia, and sudden death); all-cause mortality. Over 10
years, haemoglobin A1c (HbA1c) was 7.0% (6.2-8.2) in the intensive group compared with 7.9%
(6.9-8.8) in the conventional group--an 11% reduction. There was no difference in HbA1c
among agents in the intensive group. Compared with the conventional group, the risk in the
intensive group was 12% lower (95% CI 1-21, p=0.029) for any diabetes-related endpoint; 10%
lower (-11 to 27, p=0.34) for any diabetes-related death; and 6% lower (-10 to 20, p=0.44) for all-
cause mortality. Most of the risk reduction in the any diabetes-related aggregate endpoint was
due to a 25% risk reduction (7-40, p=0.0099) in microvascular endpoints, including the need
for retinal photocoagulation [77].
16. Veterans affairs cooperative study
Veterans Affairs Cooperative Study proved that intensive glycemic control retards microal‐
buminuria in patients who have had type 2 diabetes for several years but may not lessen the
progressive deterioration of glomerular function. 153 male patients to either intensive
treatment (INT) (goal HbA(1c) 7.1%) or to standard treatment (ST) (goal HbA(1c) 9.1%; P =
0.001), and data were obtained during a 2-year period. Mean duration of known diabetes was
8 years, mean age of the patients was 60 years, All patients were treated with insulin. INT
retarded the progression of microalbuminuria during the 2-year period: the changes in
albumin:creatinine ratio from baseline to 2 years of INT versus ST were 0.045 vs. 0.141,
respectively (P = 0.046). Retardation of progressive urinary albumin excretion was most
Diabetes Mellitus Type 2 and Proteinuria
http://dx.doi.org/10.5772/56434
219
pronounced in those patients who entered the study with microalbuminuria and were
randomized to INT. Patients entering with microalbuminuria had a deterioration in creatinine
clearance at 2 years regardless of the intensity of glycemic control.The unexplainined finding
was that in the group entering without microalbuminuria, the subgroup receiving ST had a
lower percentage of patients with a macrovascular event (17%) than the subgroup receiving
INT (36%) (P = 0.03) [78].
17. ACCORD
ACCORD study concluded that microvascular benefits of intensive therapy should be weighed
against the increase in total and cardiovascular disease-related mortality, increased weight
gain, and high risk for severe hypoglycaemia. 10251 patients were randomly assigned, 5128 to
the intensive glycaemia control group and 5123 to standard group. Intensive therapy was
stopped before study end because of higher mortality in that group, and patients were
transitioned to standard therapy. At transition, the first composite outcome was recorded in
443 of 5107 patients in the intensive group versus 444 of 5108 in the standard group (HR 1.00,
95% CI 0.88-1.14; p=1.00), and the second composite outcome was noted in 1591 of 5107 versus
1659 of 5108 (0.96, 0.89-1.02; p=0.19). Results were similar at study end (first composite outcome
556 of 5119 vs 586 of 5115 [HR 0.95, 95% CI 0.85-1.07, p=0.42]; and second 1956 of 5119 vs 2046
of 5115, respectively [0.95, 0.89-1.01, p=0.12]). Intensive therapy did not reduce the risk of
advanced measures of microvascular outcomes, but delayed the onset of albuminuria and
some measures of eye complications and neuropathy [79].
18. VADT
VADT study investigated the intensive glucose control in patients with poorly controlled type
2 diabetes had no significant effect on the rates of major cardiovascular events, death, or
microvascular complications with the exception of progression of albuminuria (P = 0.01). 1791
military veterans (mean age, 60.4 years) who had a suboptimal response to therapy for type 2
diabetes were assigned to receive either intensive or standard glucose control. The goal in the
intensive-therapy group was an absolute reduction of 1.5 percentage points in the glycated
hemoglobin level, as compared with the standard-therapy group. The primary outcome was
the time from randomization to the first occurrence of a major cardiovascular event, a com‐
posite of myocardial infarction, stroke, death from cardiovascular causes, congestive heart
failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic
gangrene. The median follow-up was 5.6 years. Median glycated hemoglobin levels were 8.4%
in the standard-therapy group and 6.9% in the intensive-therapy group. The primary outcome
occurred in 264 patients in the standard-therapy group and 235 patients in the intensive-
therapy group (hazard ratio in the intensive-therapy group, 0.88; 95% confidence interval [CI],
0.74 to 1.05; P=0.14). There was no significant difference between the two groups in any
component of the primary outcome or in the rate of death from any cause (hazard ratio, 1.07;
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95% CI, 0.81 to 1.42; P=0.62). No differences between the two groups were observed for
microvascular complications. The rates of adverse events, predominantly hypoglycemia, were
17.6% in the standard-therapy group and 24.1% in the intensive-therapy group [80].
19. Kumato study
Kumato study investigated a total of 110 Japanese patients with type 2 diabetes (55 with no
retinopathy [the primary prevention cohort] and 55 with simple retinopathy [the secondary
intervention cohort]) in an 8-year prospective study. The patients were randomly assigned to
multiple insulin injection therapy (MIT) groups and administered three or more daily insulin
injections or assigned to conventional insulin injection therapy (CIT) groups and administered
one or two daily intermediate-acting insulin injections. Worsening of microvascular compli‐
cations was regularly assessed during 8 years. In both primary prevention and secondary
intervention cohorts, the cumulative percentages of worsening in retinopathy and nephrop‐
athy were significantly lower (P < 0.05) in the MIT group than in the CIT group. In neurological
tests after 8 years, the MIT group showed significant improvement (P < 0.05) in the median
nerve conduction velocities (motor and sensory nerves), whereas the CIT group showed
significant deterioration (P < 0.05) in the nerve conduction velocities and vibration threshold.
From this study, the glycemic threshold to prevent the onset and progression of diabetic
microvascular complications was as follows: HbA1c < 6.5%, fasting blood glucose concentra‐
tion < 110 mg/dl, and 2-h postprandial blood glucose concentration < 180 mg/dl [81]. Moreover,
antihypertensive therapy and improved glycaemic control were independent predictors for
remission. 151 patients with type 2 diabetes and microalbuminuria at baseline in whom GFR
was measured at least three times during 7.8 years of follow-up were divided into three groups
according to the level of albuminuria during follow-up. Overt nephropathy was diagnosed as
a UAER>300 mg/24 h and remission to normoalbuminuria was defined as an UAER<30
mg/24 h at the last examination. During follow-up, 46 patients achieved remission to nor‐
moalbuminuria, 58 remained microalbuminuric and 47 patients progressed to overt nephr‐
opathy. The mean (+/- SE) yearly decline in GFR was lowest (2.3+/-0.4 ml/min/year) in patients
who obtained remission, in comparison with patients remaining microalbuminuric, in
whomthe decline was 3.7+/-0.4 ml/min/year, and patients progressing to overt nephropathy,
who had a decline in GFR of 5.4+/-0.5 ml/min/year (ANOVA, P<0.001). Start of antihyperten‐
sive treatment during follow-up was strongly associated with remission to normoalbuminuria
[odds ratio: 2.32; 95% confidence interval (CI): 1.09-4.93] whereas a decrease in HbA(1c) by 1%
increased the probability for remission (odds ratio: 1.48; 95% CI: 1.11-1.97) [82]
20. Other diabetic treatment strategies
Other treatments were developed in addition to blood pressure control, glucose control and
renin-angiotensin system blockade to slow kidney function deterioration. We will briefly
discuss some of them.
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• Vitamin D receptor (VDR) agonists. The main sources of vitamin D3 are diet and skin under
the influence of solar ultraviolet action. Vitamin D3 is activated to 1,25dihydroxyvitamin
D3 [1,25(0H)2 D3] by liver and kidney. VDR agonists are renal protective in diabetic patients.
VDR agonists slow renal fibrosis through RAS blockade and have synergic effects in
combinations ACE inhibitors or ARBS [83]. Two of VDR agonists, doxercalciferol and
paricalcitol decrease proteinuria. Doxercalciferol effect was investigated in diet-induced
obesity mice Proteinuria,, renal mesangial expansion and podocytes injury were slowed by
doxercalciferol. Doxercalciferol also diminished oxidative stress, macrophage infiltration
and profibrotic growth factors [84]. Paricalcitol was investigated in Vital study. Paricalcitol
had a synergic effect with ACE inhibitors and ARBs and reduced proteinuria in type 2
diabetic patients [85].
• Farnesoid X receptor agonists (FXR). The hydrophobic bile acid, chenodeoxycholic acid,
activates FXR and has an important role in preventing atherosclerosis, and controlling
metabolic and bile acid homeostasis [86]. FXR was detected in kidney and other organs like
liver and adrenal gland [87]. FXR agonists was investigated in FXR knockout mice. The
studies proved that FXR agonists diminished proteinuria, glomerulosclerosis, tubulointer‐
stital fibrosis and macrophage infiltration [85,88].
• AGEs inhibitors. The clinical utility of these agents remain to be proven. Studies with
aminoguanidine (pimagenide) were interrupted due to safety concern. AGE breakers ( N-
phenacylthiazodium bromide and alagebrium chloride), anti-RAGE antibodies were used
only in experimental models. Pyridoxamine ( vitamin B6 derivate), an AGEs inhibitor,
reduced proteinuria in several studies [89,90].
Pirfenidone and Bartoxolone. Pirfenidone [5-methyl-1-phenyl-2(1H)-pyrodone] is a synthetic
antifibrotic agent. Pirfenidone blocks TGF- β promoter and secretron and reduces tubular and
glomerural lesions in experimental models [91]. Bardoxolone has an antiinflamatory effect and
acts through Nrf2 pathway. Nrf2 is a transcription factor controlling antioxidant genes that
help maintain redox homeostasis. A phase 2, double-blind, randomized, placebo-controlled
trial investigated the role of bardoxolone. 227 adults with CKD (defined as an estimated
glomerular filtration rate [GFR] of 20 to 45 ml per minute per 1.73 m(2) of body-surface area)
in a 1:1:1:1 ratio were assigned to receive placebo or bardoxolone methyl at a target dose of 25,
75, or 150 mg once daily. The primary outcome was the change from baseline in the estimated
GFR with bardoxolone methyl, as compared with placebo, at 24 weeks; a secondary outcome
was the change at 52 weeks. Patients receiving bardoxolone methyl had significant increases
in the estimated GFR, as compared with placebo, at 24 weeks (with between-group differences
per minute per 1.73 m(2) of 8.2±1.5 ml in the 25-mg group, 11.4±1.5 ml in the 75-mg group, and
10.4±1.5 ml in the 150-mg group; P<0.001). The increases were maintained through week 52,
with significant differences per minute per 1.73 m2 of 5.8±1.8 ml, 10.5±1.8 ml, and 9.3±1.9 ml,
respectively. Muscle spasms, the most frequent adverse event in the bardoxolone methyl
groups, were generally mild and dose-related. Hypomagnesemia, mild increases in alanine
aminotransferase levels, and gastrointestinal effects were more common among patients
receiving bardoxolone methyl [92].
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21. Conclusion
Microalbuminuria and proteinuria are common complications among patients with type 2
diabetes. Proteinuria is a predictive factor for cardiovascular events, and cardiovascular and
all-cause mortality. Microalbuminuria is defined as persistent urinary albumin excretion
between 30 and 300 mg/day (20 to 200 µg/min). Macroalbuminuria refers to albumin excretion
above 300 mg/day (200 µg/min). Patients with diabetes mellitus type 2 must be screened
annually for proteinuria, starting at diagnosis. Measurement of the albumin:creatinine ratio in
a first-morning void is the superior method to predict renal events in patients with type 2
diabetes and nephropathy, but the difference compared to spot urine samples at other times
was not significant. Intervention studies in microalbuminuric type 2 diabetic patients have
demonstrated that it is possible to avoid progression to overt diabetic nephropathy and even
to achieve regression to normoalbuminuria. The best therapeutic strategy is a multifactorial
approach including glycemic control, blood pressure control, renin-angiotensin inhibition and
lifestyle modification.
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